An interventional study of Educational Information via Smartphone App in Colorectal Cancer (CRC) Screening, sponsored by Baylor Research Institute. Not yet recruiting at 1 site in United States. Open to participants aged 45 Years to 84 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Baylor Research Institute · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 2,342 studies in Colorectal Neoplasms with a site in United States — 415 open to participants now, 629 under way, 30 of them phase 3. Colorectal Neoplasms · United States.
Among the 2,342 studies in Colorectal Neoplasms with a site in United States, this one is the 44th largest by planned enrollment of the 1,934 interventional ones that give a count, is one of 120 that started in 2026, is one of 533 with no phase, reaches primary completion later than 263 of the 627 other live ones, and was the 2,254th registered.
6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →415 of the 2,342 studies in Colorectal Neoplasms with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18+
Exelixis · Sites in United States
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 40–80 · Men only
Incyte Corporation · Sites in United States, Puerto Rico
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 45 Years to 84 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,342 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 818 · Phase 2 793 · Phase 3 132 · Phase 4 19
First in 1981; this study’s year is marked. 120 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 5,500 is above the median of 76 across 4,811 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 64 across the 1,934 interventional studies, 220 across the 325 observational. Of the 1,566 that completed or were terminated, 551 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
887 of 2,342 have an industry lead sponsor. The 10 most frequent:
Baylor Research Institute is the lead sponsor of 224 studies on the registry; 48 are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 9 (39%) have results posted.
Baylor Research Institute has 1 study filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
226 of the studies in Colorectal Neoplasms with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05141721Phase 3Seattle Project CorporationA Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer | 2027-03 |
| NCT04428905Phase 3City of Hope Medical CenterSelf-Management Survivorship Care in Stage I-III Non-small Cell Lung Cancer or Colorectal Cancer | 2027-03-31 |
| NCT02997228Phase 3National Cancer Institute (NCI)Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study | 2027-06-01 |
| NCT01349881Phase 3SWOG Cancer Research NetworkS0820, Adenoma and Second Primary Prevention Trial | 2027-09-15 |
| NCT03796884Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityLinaclotide in Treating Patients With Stages 0-3 Colorectal Cancer | 2026-11 |
Add all 226 to your calendar (.ics) → With an account.
Among the 2,342 studies in Colorectal Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this prospective implementation study is to understand the impact of a blood-based screening test (BBST) for colorectal cancer (CRC) on patient acceptability of and adherence to CRC screening as well as the rate of follow-up BBST in those with negative BBST at a 1-year interval.
Additional aims include assessing the impact of digital patient navigation intervention on the rate of follow-up colonoscopy in individuals with positive BBST. Patients will be randomized into the non-intervention arm or the intervention with an app arm.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients on the app intervention arm will receive educational messages via their healthcare portal smartphone app.
Other: Educational Information via Smartphone App
Patients on the standard support arm who receive a positive blood test result and either do not access their healthcare portal smartphone app and/or do not schedule a colonoscopy within 2 weeks of the blood test result will receive the standard patient navigation support offered which typically includes explanation and education regarding their positive test result and referral to a gastroenterologist or other proceduralist for a colonoscopy.
The educational messages will include information about the meaning of a positive test result, the patient's chances of having a CRC detected on colonoscopy, and the importance of early CRC detection.
Blood-Based Screening Test (BBST) Follow-Up
Assess the number of patients with a negative BBST result who accept and complete a follow-up BBST.
Time frame: 1 year after initial result
Patient Screening Test Preference
Assess patient preference rates and test completion rates for stool tests, colonoscopy, and blood-based CRC screening modalities.
Time frame: 1 year
Screening Rates
Compare the overall screening rates in the study population to a historical cohort in which blood-based testing was not offered as an option.
Time frame: 1 year
Intervention Efficacy
Assess whether use of a digital patient navigation tool +/- traditional patient navigation leads to an increased rate of completion of colonoscopy in those with a positive blood or stool test.
Time frame: 1 year
Baseline BBST Results
Number of positive and negative BBST results at baseline testing.
Time frame: 1 year
Follow-Up BBST Results
Number of positive and negative BBST results at follow-up test
Time frame: 1 year after initial result
BBST+ Follow-Up
Number of BBST positives who received follow-up colonoscopy
Time frame: 1 year
BBST+/Colonoscopy- Follow-Up
Percentage of BBST-positive/colonoscopy-negative patients who accept and complete the follow-up BBST after negative colonoscopy.
Time frame: 1 year after negative colonoscopy
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Jun 2027, 7 months later.
Of 900 non-industry interventional studies with no phase under Colorectal Neoplasms, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 61. This study's planned 7 months is below that.
Counting every sponsor, half of 958 studies reached it within 31 months; a quarter within 14 and three quarters within 60.
Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Nov 2026, on Nov 2, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.